FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308125636> ?p ?o ?g. }

• W4308125636 abstract "Objective: This network meta-analysis aimed to explore the effect of different drugs on mortality and neurological improvement in patients with traumatic brain injury (TBI), and to clarify which drug might be used as a more promising intervention for treating such patients by ranking. Methods: We conducted a comprehensive search from PubMed, Medline, Embase, and Cochrane Library databases from the establishment of the database to 31 January 2022. Data were extracted from the included studies, and the quality was assessed using the Cochrane risk-of-bias tool. The primary outcome measure was mortality in patients with TBI. The secondary outcome measures were the proportion of favorable outcomes and the occurrence of drug treatment–related side effects in patients with TBI in each drug treatment group. Statistical analyses were performed using Stata v16.0 and RevMan v5.3.0. Results: We included 30 randomized controlled trials that included 13 interventions (TXA, EPO, progesterone, progesterone + vitamin D, atorvastatin, beta-blocker therapy, Bradycor, Enoxaparin, Tracoprodi, dexanabinol, selenium, simvastatin, and placebo). The analysis revealed that these drugs significantly reduced mortality in patients with TBI and increased the proportion of patients with favorable outcomes after TBI compared with placebo. In terms of mortality after drug treatment, the order from the lowest to the highest was progesterone + vitamin D, beta-blocker therapy, EPO, simvastatin, Enoxaparin, Bradycor, Tracoprodi, selenium, atorvastatin, TXA, progesterone, dexanabinol, and placebo. In terms of the proportion of patients with favorable outcomes after drug treatment, the order from the highest to the lowest was as follows: Enoxaparin, progesterone + vitamin D, atorvastatin, simvastatin, Bradycor, EPO, beta-blocker therapy, progesterone, Tracoprodi, TXA, selenium, dexanabinol, and placebo. In addition, based on the classification of Glasgow Outcome Scale (GOS) scores after each drug treatment, this study also analyzed the three aspects of good recovery, moderate disability, and severe disability. It involved 10 interventions and revealed that compared with placebo treatment, a higher proportion of patients had a good recovery and moderate disability after treatment with progesterone + vitamin D, Bradycor, EPO, and progesterone. Meanwhile, the proportion of patients with a severe disability after treatment with progesterone + vitamin D and Bradycor was also low. Conclusion: The analysis of this study revealed that in patients with TBI, TXA, EPO, progesterone, progesterone + vitamin D, atorvastatin, beta-blocker therapy, Bradycor, Enoxaparin, Tracoprodi, dexanabinol, selenium, and simvastatin all reduced mortality and increased the proportion of patients with favorable outcomes in such patients compared with placebo. Among these, the progesterone + vitamin D had not only a higher proportion of patients with good recovery and moderate disability but also a lower proportion of patients with severe disability and mortality. However, whether this intervention can be used for clinical promotion still needs further exploration." @default.
• W4308125636 created "2022-11-08" @default.
• W4308125636 creator A5009884211 @default.
• W4308125636 creator A5016245552 @default.
• W4308125636 creator A5017917541 @default.
• W4308125636 creator A5032451060 @default.
• W4308125636 creator A5039737834 @default.
• W4308125636 creator A5044300185 @default.
• W4308125636 creator A5060750182 @default.
• W4308125636 creator A5074640570 @default.
• W4308125636 creator A5076005602 @default.
• W4308125636 creator A5090650583 @default.
• W4308125636 date "2022-11-02" @default.
• W4308125636 modified "2023-10-14" @default.
• W4308125636 title "Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis" @default.
• W4308125636 cites W1833381290 @default.
• W4308125636 cites W1919733752 @default.
• W4308125636 cites W1987111435 @default.
• W4308125636 cites W1987151925 @default.
• W4308125636 cites W1995776925 @default.
• W4308125636 cites W1997395738 @default.
• W4308125636 cites W2004474087 @default.
• W4308125636 cites W2027592211 @default.
• W4308125636 cites W2028627947 @default.
• W4308125636 cites W2028915915 @default.
• W4308125636 cites W2035912847 @default.
• W4308125636 cites W2041590252 @default.
• W4308125636 cites W2045906519 @default.
• W4308125636 cites W2046037876 @default.
• W4308125636 cites W2059003912 @default.
• W4308125636 cites W2096869950 @default.
• W4308125636 cites W2106757656 @default.
• W4308125636 cites W2132429284 @default.
• W4308125636 cites W2141580262 @default.
• W4308125636 cites W2154507530 @default.
• W4308125636 cites W2162249417 @default.
• W4308125636 cites W2166531273 @default.
• W4308125636 cites W2288653246 @default.
• W4308125636 cites W2299568419 @default.
• W4308125636 cites W2410225469 @default.
• W4308125636 cites W2474156373 @default.
• W4308125636 cites W2494112084 @default.
• W4308125636 cites W2508063686 @default.
• W4308125636 cites W2519065143 @default.
• W4308125636 cites W2550928277 @default.
• W4308125636 cites W2586825713 @default.
• W4308125636 cites W2588639870 @default.
• W4308125636 cites W2727957981 @default.
• W4308125636 cites W2749724913 @default.
• W4308125636 cites W2763078187 @default.
• W4308125636 cites W2765918605 @default.
• W4308125636 cites W2767813783 @default.
• W4308125636 cites W2777050377 @default.
• W4308125636 cites W2781482452 @default.
• W4308125636 cites W2785140707 @default.
• W4308125636 cites W2803739912 @default.
• W4308125636 cites W2808807768 @default.
• W4308125636 cites W2889292408 @default.
• W4308125636 cites W2893346879 @default.
• W4308125636 cites W2900114306 @default.
• W4308125636 cites W2909539006 @default.
• W4308125636 cites W2914333748 @default.
• W4308125636 cites W2914892110 @default.
• W4308125636 cites W2936760264 @default.
• W4308125636 cites W2971546983 @default.
• W4308125636 cites W2975048791 @default.
• W4308125636 cites W3003760543 @default.
• W4308125636 cites W3005742140 @default.
• W4308125636 cites W3047389494 @default.
• W4308125636 cites W3083944649 @default.
• W4308125636 cites W3084265249 @default.
• W4308125636 cites W3092703164 @default.
• W4308125636 cites W3204029574 @default.
• W4308125636 cites W3204106835 @default.
• W4308125636 cites W3210212678 @default.
• W4308125636 cites W4211043869 @default.
• W4308125636 doi "https://doi.org/10.3389/fphar.2022.1021653" @default.
• W4308125636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36408253" @default.
• W4308125636 hasPublicationYear "2022" @default.
• W4308125636 type Work @default.
• W4308125636 citedByCount "0" @default.
• W4308125636 crossrefType "journal-article" @default.
• W4308125636 hasAuthorship W4308125636A5009884211 @default.
• W4308125636 hasAuthorship W4308125636A5016245552 @default.
• W4308125636 hasAuthorship W4308125636A5017917541 @default.
• W4308125636 hasAuthorship W4308125636A5032451060 @default.
• W4308125636 hasAuthorship W4308125636A5039737834 @default.
• W4308125636 hasAuthorship W4308125636A5044300185 @default.
• W4308125636 hasAuthorship W4308125636A5060750182 @default.
• W4308125636 hasAuthorship W4308125636A5074640570 @default.
• W4308125636 hasAuthorship W4308125636A5076005602 @default.
• W4308125636 hasAuthorship W4308125636A5090650583 @default.
• W4308125636 hasBestOaLocation W43081256361 @default.
• W4308125636 hasConcept C118552586 @default.
• W4308125636 hasConcept C126322002 @default.
• W4308125636 hasConcept C142724271 @default.
• W4308125636 hasConcept C168563851 @default.
• W4308125636 hasConcept C204787440 @default.
• W4308125636 hasConcept C27081682 @default.
• W4308125636 hasConcept C2776329913 @default.

• next